Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.50 Consensus Price Target from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in the last year is $12.50.

STRO has been the subject of several recent research reports. Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Sutro Biopharma in a report on Tuesday, May 14th. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Sutro Biopharma in a research note on Tuesday, May 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $11.00 price target (down previously from $12.00) on shares of Sutro Biopharma in a research report on Wednesday, April 3rd. Oppenheimer reissued an “outperform” rating and set a $10.00 price objective on shares of Sutro Biopharma in a research report on Wednesday, May 15th. Finally, Bank of America assumed coverage on shares of Sutro Biopharma in a report on Wednesday, May 8th. They issued a “buy” rating and a $12.00 target price for the company.

Institutional Trading of Sutro Biopharma

A number of large investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its holdings in Sutro Biopharma by 24.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock worth $102,000 after purchasing an additional 3,578 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Sutro Biopharma by 25.6% in the 4th quarter. SG Americas Securities LLC now owns 40,779 shares of the company’s stock worth $175,000 after buying an additional 8,314 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in shares of Sutro Biopharma by 14,125.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 8,820 shares of the company’s stock worth $38,000 after acquiring an additional 8,758 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Sutro Biopharma during the fourth quarter valued at $60,000. Finally, Lazard Asset Management LLC bought a new position in Sutro Biopharma in the first quarter valued at about $92,000. 96.99% of the stock is currently owned by institutional investors.

Sutro Biopharma Stock Down 4.9 %

Shares of STRO stock opened at $4.07 on Friday. The business’s fifty day moving average is $3.68 and its 200 day moving average is $4.12. The stock has a market cap of $332.89 million, a price-to-earnings ratio of -2.16 and a beta of 1.23. Sutro Biopharma has a twelve month low of $2.01 and a twelve month high of $6.13.

Sutro Biopharma (NASDAQ:STRO) last released its earnings results on Monday, May 13th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.03). Sutro Biopharma had a negative return on equity of 94.18% and a negative net margin of 74.61%. The business had revenue of $13.01 million during the quarter, compared to analysts’ expectations of $11.57 million. Equities research analysts expect that Sutro Biopharma will post -3.5 earnings per share for the current fiscal year.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.